Candia et al. started to use a binding peptide (P60) that affects Foxp3 nuclear translocation and could effectively inhibit the tumor-intrinsic effect of Foxp3 in experimental BC, and reduces tumor cell viability and migration [246]. The gene discussed is TNFRSF1A; the disease is breast cancer.